Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.37 |
| ▸ | NAMPT | P43490 | 10/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CALML3 | P27482 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2822507 | 0.84 | GRM2 (0.56) | GRM2 | |
| SCHEMBL2827882 | 0.80 | GRM2 (0.52) | GRM2 | |
| SCHEMBL2828441 | 0.80 | GRM2 (0.37) | GRM2TRPV1CALML3 | |
| SCHEMBL2823842 | 0.78 | GRM2 (0.42) | GRM2 | |
| SCHEMBL2823359 | 0.72 | GRM2 (0.66) | GRM2 | |
| SCHEMBL8008418 | 0.70 | GRM2 (0.61) | GRM2 | |
| SCHEMBL2826288 | 0.69 | GRM2 (0.47) | GRM2 | |
| SCHEMBL2823362 | 0.67 | GRM2 (0.74) | GRM2 | |
| SCHEMBL2822625 | 0.67 | GRM2 (0.45) | GRM2 | |
| SCHEMBL2823453 | 0.64 | GRM2 (0.56) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-11-18 | — | — | US | claimed |
| EP-2244576-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2010-11-03 | — | — | EP | claimed |
| WO-2009094265-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK & CO., INC. (US) | 2009-07-30 | — | — | WO | claimed |
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2244576-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009094265-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK & CO., INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094265-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK & CO., INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | GRM2, GRM3, GRM1 | GRM2 1/4885NAMPT 3254/4885TRPV1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.